



EVER 2021
**E-poster week &
Virtual Congress**
27 September - 2 October 2021

**SCIENTIFIC
PROGRAM**

**THE
2021 EVER
FESTIVAL**

Scientific sections

ACB

Anatomy / Cell Biology

COS

Cornea / Ocular Surface

EOVS

Electrophysiology, Physiological Optics, Vision Sciences

G

Glaucoma

IM

Immunology / Microbiology

LC

Lens and Cataract

MBGE

Molecular Biology / Genetics / Epidemiology

NSPH

Neuro-ophthalmology/Strabismology /
Paediatric Ophthalmology / History of Ophthalmology

PO

Pathology / Oncology

PBP

Physiology / Biochemistry / Pharmacology

RV

Retina / Vitreous Section programme secretaries

EVER 2021 INDUSTRY WEBINAR - 27 SEPTEMBER

21.00-22.00

see pag. 9

EVER 2021 VIRTUAL CONGRESS - 2 OCTOBER

09.30-10.25

Session 1

Moderator: **Dominique Bremond-Gignac**, France

- | | | |
|-------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09.30 | ACB | Surgical aspects of RPE cell therapy for AMD
Boris V. Stanzel , Germany |
| 09.40 | COS | Advances and Innovations in Eye Banking and Tissue Processing for Corneal Transplantation
Zisis Gatzoufas , Switzerland |
| 09.50 | EOVS | Contribution of adaptive optics ophthalmoscopy to the investigation of the Stiles-Crawford effect in retinal diseases
Michel Paques , France |
| 10.00 | G | Gene therapy for optic nerve protection and repair
Keith Martin , Australia |
| 10.10 | | LIVE Q & A |

10.30-11.25

Session 2

Moderator: **Manuel Vidal-Sanz**, Spain

10.30

IM Cutting-edge imaging for Uveitis
Francesco Pichi, Italy

10.40

LC Corneal Regeneration: Is it possible?
Jorge Alio, Spain

10.50

MBGE MicroRNA-mRNA genetic networks in refractive eye development and myopia
Andrei V. Tkatchenko, United States

11.00

NSPH Optic Neuritis and Anti-What?: The NMO and MOG story
John J. Chen, United States

11.10

LIVE Q & A

11.30-12.15

Session 3

Moderator: **Frédéric Mouriaux**, France

11.30

PO MR Imaging of Uveal Melanoma with Clinicopathological Correlations
Teresa Ferreira, Netherlands

11.40

PBV Retinal energy metabolism in vascular and avascular retinas
Glyn Chidlow, United States

11.50

RV Venous Overload Choroidopathy: Associated Conditions
Richard F. Spaide, United States

12.00

LIVE Q & A

12.15-13.00

Industry Lunch Symposium see pag. 10

13.00-13.45

Industry Lunch Symposium see pag. 10

14.00-14.45

Session 4 - Rapid Fire

Moderators: **Kai Kaarniranta**, Finland,
Marcela Votruba, United Kingdom

- 14.00** **ACB** Phloretin reduced the secretion of IL-8 in retinal pigment epithelial cells suffering from mitochondrial dysfunction via activation of nuclear factor erythroid 2 related factor 2 (NFE2L2/Nrf2)
Maria Hytti, Finland
- 14.05** **COS** A unique pre-endothelial layer at the posterior peripheral cornea: Ultra-structural study
Saeed Akhtar, Saudi Arabia
- 14.10** **EOVS** Neuronal sources of visually evoked potentials using selective color opponent channel stimulation
Sascha Klee, Germany
- 14.15** **G** Multivariate normative comparison, a novel method for improved use of the retinal nerve fiber layer thickness to detect early glaucoma
Jacqueline Chua, Singapore
- 14.20** **IM** Vision-related quality of life in spondyloarthritis patients with history of acute anterior uveitis under treatment with golimumab: preliminary results of the GO-VISION observational stud
Ines Leal, Portugal
- 14.25** **LC** A comparative study of difluprednate 0.05% Nanoemulsion vs prednisolone acetate 1% + phenylephrine 0.12% Suspension on postoperative inflammation treatment following cataract surgery
Melina Sol del Papa, Argentina
- 14.30** **LIVE Q & A**

14.50-15.30

Session 5 - Rapid Fire

Moderators: **Manuel Vidal-Sanz**, Spain,
Roy Andrew Quinlan, United Kingdom

- 14.50 **MBGE** Pharmacogenetics. Phenotype And Genotype Response To Prostaglandin Analogues And Beta Blockers In A Population Of Glaucoma Patients
Valeria Opazo Toro, Spain
- 14.55 **NSPH** Retina Analysis With Optical Coherence Tomography In Patients With Fibromyalgia
Beatriz Cordón Ciordia, Spain
- 15.00 **PO** The effects of visible and blue light exposure on growth and melanogenesis of ocular melanoma cell lines
Chieh-Lin (Stanley) Wu, Australia
- 15.05 **PBV** Ten differentially expressed proteins in the tear film of dogs with diabetic retinopathy
Dagmara Winiarczyk, Poland
- 15.10 **RV** Comparison of quantitative self-monitoring metamorphopsia measurements tools in myopic choroidal neovascularization (mCNV)
Katja Hatz, Switzerland
- 15.15 **LIVE Q & A**

15.35-16.15

Session 6 - Young Investigators

Moderators: **João Barbosa Breda**, Portugal,
Francesca Cordeiro, United Kingdom

- | | | |
|-------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15.35 | ACB | Effect of systemic immunosuppression and BM-MSCT allotransplantation in retinal functionality and RGC population
María Norte Muñoz , Spain |
| 15.40 | COS | Dendritic cell depletion modifies corneal nerve activity and mice nociceptive behaviour
Laura Rincon Frutos , Spain |
| 15.45 | EOVS | Evaluation of the effect of eye movements on the Sweep VEP
Ioannis Dimopoulos , Canada |
| 15.50 | G | Glaucoma clinical research: Trends in treatment strategies and drug discovery
Josefine Clement Freiberg , Denmark |
| 15.55 | IM | Cytokine profile in tear and aqueous humor of primary open-angle glaucoma patients as a prognostic factor for trabeculectomy outcome
Barbara Burgos-Blasco , Spain |
| 16.00 | LC | Spontaneous Lens Subluxation Into Anterior Chamber. Importance Of An Early Management
Ismael Bakkali El Bakkali , Spain |
| 16.05 | | LIVE Q & A |

16.20-16.55

Session 7 - Young Investigators

Moderator: **Dominique Bremond-Gignac**, France

- 16.20 **MBGE** Effects of Inhibition of Wnt/beta-catenin Pathway on Amacrine and Muller cells in Retinas of Zebrafish Embryos at Different Development Stages
Ayşe Ipek Akyuz Unsal, Turkey
- 16.25 **NSPH** Retinal Neurodegeneration And Neuroinflammation In A Sod1 Mouse Model Of Als
María Pilar Rojas Lozano, Spain
- 16.30 **PO** Radiological work-up for proton beam therapy of uveal melanoma patients
Myriam Jaarsma-Coes, Netherlands
- 16.35 **PBV** Decreased docosahexaenoic acid and other specific fatty acids in a mouse model of retinal degeneration
María José Ruiz Pastor, Spain
- 16.40 **RV** Identification of eleven differentially expressed proteins in the tear film of patients with neovascular Age-related Macular Degeneration (AMD)
Mateusz Winiarczyk, Poland
- 16.45 **LIVE Q & A**

17.00-17.10

AWARDS

17.10-17.40

GENERAL ASSEMBLY

INDUSTRY WEBINAR - 27 SEPTEMBER

21.00-22.00

Learning from the learners

Moderators: **Harminder Dua**, United Kingdom,
Miriam Kolko, Denmark,
João Barbosa Breda, Portugal

Management of glaucoma patients in 2021
Anthony Khawaja, United Kingdom

Dry eye treat it as a disease
Antoine Rousseau, France

Cornea Surgery Technics
Giuseppe Giannaccare, Italy

Tricks in complicated Cataract Surgery
Panagiotis Salvanos, Greece

Tips for Retina surgery
Jelena Potic, Switzerland

Discussion



INDUSTRY SYMPOSIA - 2 OCTOBER

12.15-13.00

How to treat evaporative dry eye associated with MGD in clinical practice?



Moderator: **Kostas Boboridis, Greece**

Pathophysiology of evaporative dry eye associated with MGD
Kostas Boboridis, Greece

Treatment schemes for evaporative dry eye relief
Elisabeth Messmer, Germany

Refractory MGD - Is it Demodex?
Teifi James, United Kingdom

13.00-13.45

New perspectives in LHON management



Moderator: **Letizia Gabaglio, Italy**

Speakers: **Thomas Klopstock, Germany**
Berthold Pemp, Austria

ON DEMAND INDUSTRY SYMPOSIUM

60 min.

**Mechanisms of Action:
Steroids & Anti VEGF's,
how do they really work?**



Moderator: **Francine Behar-Cohen, France**

Acknowledgements

EVER wishes to express its gratitude to all Sponsors
for their generous support to the Congress

MAJOR SPONSORS



SPONSORS



NOT A L H N E

FOR EVER

LOSING SIGHT IS A PAIN THAT CANNOT BE INVISIBLE.

LHON is a rare eye condition that causes the loss of central vision, generally in both eyes, and can lead to blindness. As vision is lost, activities such as reading, driving and recognising faces become increasingly difficult.^{1,2}

LHON is commonly misdiagnosed as other more common optic neuropathies, delaying treatment initiation.^{3,4}

**Diagnose early and help
light up their future**

**With undiagnosed LHON,
the future looks dark**

 **Chiesi**
Global Rare Diseases 

CHHQ-INT-0032

¹ Mascialino B et al. Eur J Ophthalmol. 2012;22(3):461-5.

² Yu-Wai-Man P et al. J Med Genet. 2009;46(3):145-58.

³ Sadun AA et al. Expert Rev Ophthalmol. 2012;7(3):251-9.

⁴ Carelli V et al. J Neuroophthalmol. 2017;37(4):37181.



let's open our eyes

LABORATOIRES-THEA.COM

Théa is a profoundly European company whose independence, stability and entrepreneurial spirit are safeguarded by the Chibret family, which has been instrumental in the field of ophthalmology for over 150 years. This family governance model focuses on Théa, its employees, people values and long-term development to fulfill our mission: to be the "Ophthalmology Specialist".

Pioneer in preservative-free eye care treatments, our commitment is to provide innovative products and a wide range of medicinal products (service products, daily-use products) to healthcare providers and patients in all ophthalmological therapeutic classes.

We constantly reinvest in Théa's two priority areas of Innovation and Internationalisation, with long-term strategy outweighing short-term profit. Our objectives are continuity, enhancing long-term partnerships and collaborative research, transmitting our knowledge, tackling unmet medical needs by offering new treatment or patient support models.

Internationalisation is rooted in our genes: Théa is currently the first independent ophthalmology laboratory in Europe, and aims to become a world leader in terms of export and international presence in compliance with the culture of each country where it is present.

**It is this vision that
makes Théa unique.**



Laboratoires Théa
12 rue Louis-Blériot, 63000 Clermont-Ferrand
FRANCE

